Other Events ·
Apimeds Pharmaceuticals US, Inc. filed a Current Report on Form 8-K disclosing the execution of an amendment to its…
APUSApimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals US, Inc. filed a Current Report on Form 8-K disclosing the execution of an amendment to its Confidential Settlement and Mutual Release Agreement dated September 10, 2026. The amendment restructures the company's board composition, establishing an interim board of four directors who cannot be removed without consent from Dr. Vin Menon and the Inscobee Parties. Following this period, the board will expand to seven members, including independent directors nominated by MindWave Innovations Inc., two nominees from Dr. Menon (one being himself), and Sungjoon Chae. Concurrently, Sungjoon Chae was appointed to the Board of Directors effective September 10, 2026, pursuant to nominations by the Inscobee Parties under the settlement terms. Mr. Chae has served as Co-Chief Executive Officer since May 4, 2026 and holds degrees from the Illinois Institute of Technology and Harvard University with expertise in urban design and real estate development. Apimeds Pharmaceuticals US, Inc. operates in the pharmaceutical industry, focusing on drug discovery and development.